Go Pro
NASDAQ:CNTA

Centessa Pharmaceuticals Q1 2026 Earnings Report

Centessa Pharmaceuticals EPS Results

Actual EPS
-$0.52
Consensus EPS
-$0.38
Beat/Miss
Missed by -$0.14
One Year Ago EPS
N/A

Centessa Pharmaceuticals Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Centessa Pharmaceuticals Announcement Details

Quarter
Q1 2026
Time
Before Market Opens
Conference Call Date
Tuesday, May 5, 2026
Conference Call Time
7:00AM ET

Earnings Documents

Centessa Pharmaceuticals Earnings Headlines

How Long Does $2.5M Last in Retirement?
Having $2.5 million saved puts you ahead of most Americans, but how long it lasts depends on the decisions you make with it. Using the 4% rule as a benchmark, that balance could translate to about $100,000 in year one, adjusted upward for inflation each year after. But the 4% rule has potential downsides and may not fit every portfolio. A financial advisor can help size and structure a retirement budget around your income sources, taxes, and goals. SmartAsset's free quiz matches nearly 50,000 people each month with vetted fiduciary advisors.tc pixel
See More Centessa Pharmaceuticals Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Centessa Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Centessa Pharmaceuticals and other key companies, straight to your email.

About Centessa Pharmaceuticals

Centessa Pharmaceuticals (NASDAQ:CNTA) plc is a global clinical‐stage biopharmaceutical company focused on the discovery and development of innovative therapies across multiple disease areas. The company operates a modular R&D network, bringing together a portfolio of independent, specialist research entities under a single corporate umbrella. This structure is designed to accelerate decision‐making and resource allocation while leveraging deep scientific expertise in each therapeutic domain.

Centessa’s pipeline spans oncology, immunology, neuroscience, cardiovascular and metabolic diseases, as well as rare genetic disorders. Each affiliated research unit is advancing one or more drug candidates through discovery, preclinical studies and clinical trials. By maintaining strategic agility within its autonomous project teams, Centessa seeks to optimize development timelines and increase the probability of regulatory success.

The company was formed in 2021 through an investment consortium and completed its initial public offering via a business combination with Narwhal Acquisition Corp. in early 2022. Headquartered in Cambridge, U.K., Centessa maintains a significant presence in the United States, with research and development sites located in key biotech hubs. This transatlantic footprint enables collaboration with leading academic institutions and access to diverse clinical trial networks.

Under the leadership of Chief Executive Officer Knut Brundin, Centessa Pharmaceuticals draws on decades of industry experience to guide its strategic vision. The management team is complemented by veteran drug developers, regulatory experts and academic advisors, all committed to advancing novel therapies from laboratory research to patient care.

View Centessa Pharmaceuticals Profile